Autism and developmental disability caused by KCNQ3 gain-of-function variants.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
20
01
2019
revised:
03
06
2019
accepted:
06
06
2019
pubmed:
10
6
2019
medline:
31
3
2020
entrez:
10
6
2019
Statut:
ppublish
Résumé
Recent reports have described single individuals with neurodevelopmental disability (NDD) harboring heterozygous KCNQ3 de novo variants (DNVs). We sought to assess whether pathogenic variants in KCNQ3 cause NDD and to elucidate the associated phenotype and molecular mechanisms. Patients with NDD and KCNQ3 DNVs were identified through an international collaboration. Phenotypes were characterized by clinical assessment, review of charts, electroencephalographic (EEG) recordings, and parental interview. Functional consequences of variants were analyzed in vitro by patch-clamp recording. Eleven patients were assessed. They had recurrent heterozygous DNVs in KCNQ3 affecting residues R230 (R230C, R230H, R230S) and R227 (R227Q). All patients exhibited global developmental delay within the first 2 years of life. Most (8/11, 73%) were nonverbal or had a few words only. All patients had autistic features, and autism spectrum disorder (ASD) was diagnosed in 5 of 11 (45%). EEGs performed before 10 years of age revealed frequent sleep-activated multifocal epileptiform discharges in 8 of 11 (73%). For 6 of 9 (67%) recorded between 1.5 and 6 years of age, spikes became near-continuous during sleep. Interestingly, most patients (9/11, 82%) did not have seizures, and no patient had seizures in the neonatal period. Voltage-clamp recordings of the mutant KCNQ3 channels revealed gain-of-function (GoF) effects. Specific GoF variants in KCNQ3 cause NDD, ASD, and abundant sleep-activated spikes. This new phenotype contrasts both with self-limited neonatal epilepsy due to KCNQ3 partial loss of function, and with the neonatal or infantile onset epileptic encephalopathies due to KCNQ2 GoF. ANN NEUROL 2019;86:181-192.
Substances chimiques
KCNQ3 Potassium Channel
0
KCNQ3 protein, human
0
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-192Subventions
Organisme : University of Naples "Federico II" and Compagnia di San Paolo within the STAR Program "Sostegno Territoriale alle Attività di Ricerca"
ID : 6-CSP-UNINA-120
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS069605
Pays : United States
Organisme : University Research Fund-University of Antwerp
ID : FFB180053
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS049119
Pays : United States
Organisme : Telethon Foundation
ID : GGP15113
Pays : International
Organisme : Duke Genome Sequencing Clinic
Pays : International
Organisme : Italian Ministry for University and Research
ID : PRIN2017YH3SXK
Pays : International
Organisme : Miles Family Fund
Pays : International
Organisme : KCNQ2 Cure Alliance
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS49119
Pays : United States
Organisme : Scientific Research Flanders
ID : 1861419N
Pays : International
Organisme : Italian Ministry of Health Ricerca Finalizzata Giovani Ricercatori 2016
ID : GR-2016-02363337
Pays : International
Organisme : National Genomics Infrastructure Sweden and Science
Pays : International
Organisme : Duke University Health System
Pays : International
Organisme : Italian Ministry for University and Research
ID : RBSI1444EM
Pays : International
Informations de copyright
© 2019 American Neurological Association.